Cargando…

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years

INTRODUCTION: Solanezumab is an anti-amyloid monoclonal antibody in clinical testing for treatment of Alzheimer's disease (AD). Its mechanism suggests the possibility of slowing the progression of AD. METHODS: A possible disease-modifying effect of solanezumab was assessed using a new statistic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C., Andersen, Scott W., Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Featured Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975050/ https://www.ncbi.nlm.nih.gov/pubmed/29854931 http://dx.doi.org/10.1016/j.trci.2015.06.006

Ejemplares similares

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia
por: Willis, Brian A., et al.
Publicado: (2018)

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
por: Carlson, Christopher, et al.
Publicado: (2016)

A Novel Approach to Delayed-Start Analyses for Demonstrating Disease-Modifying Effects in Alzheimer’s Disease
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials
por: Chen, Yun-Fei, et al.
Publicado: (2016)

Delayed-start analysis for demonstrating disease modification of solanezumab
por: Wolters, Frank J., et al.
Publicado: (2015)

Function and clinical meaningfulness of treatments for mild Alzheimer's disease
por: Siemers, Eric, et al.
Publicado: (2016)

An untraditional start to my degree
por: Cutler, Catherine
Publicado: (2020)

'Dental nursing gave me a kick start'
por: Mehmood, Aisha
Publicado: (2023)

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease
por: Schwarz, Adam J., et al.
Publicado: (2019)

Jump-Starting a Cellular World: Investigating the Origin of Life, from Soup to Networks
por: Robinson, Richard
Publicado: (2005)

How Do We Start Palliative Care for Patients With End-Stage Liver Disease?
por: Kim, Sookyung, et al.
Publicado: (2022)

Struggling to get started
por: Tay, Andy
Publicado: (2020)

Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease
por: Doody, Rachelle S, et al.
Publicado: (2015)

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease
por: Wang, Guoqiao, et al.
Publicado: (2022)

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease
por: Hassan, Mubashir, et al.
Publicado: (2018)

Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
por: Liu-Seifert, Hong, et al.
Publicado: (2015)

Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
por: Joseph‐Mathurin, Nelly, et al.
Publicado: (2022)

Multiple-dose ponezumab for mild-to-moderate Alzheimer's disease: Safety and efficacy
por: Landen, Jaren W., et al.
Publicado: (2017)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease
por: Chen, Yun-Fei, et al.
Publicado: (2018)

Starting a new residency program: a step-by-step guide for institutions, hospitals, and program directors
por: Barajaz, Michelle, et al.
Publicado: (2016)

Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials
por: Ezzati, Ali, et al.
Publicado: (2022)

Predicting mild cognitive impairment from spontaneous spoken utterances
por: Asgari, Meysam, et al.
Publicado: (2017)

The effect of statins on rate of cognitive decline in mild cognitive impairment
por: Smith, Kyle B., et al.
Publicado: (2017)

Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease
por: Ballard, Clive, et al.
Publicado: (2019)

Use and costs of services and unpaid care for people with mild-to-moderate dementia: Baseline results from the IDEAL cohort study
por: Henderson, Catherine, et al.
Publicado: (2019)

The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals
por: Dickerson, Bradford C., et al.
Publicado: (2009)

Neural and behavioral substrates of disorientation in mild cognitive impairment and Alzheimer's disease
por: Sousa, Amber, et al.
Publicado: (2015)

Health Literacy Risk in Older Adults With and Without Mild Cognitive Impairment
por: Liu, Yong B., et al.
Publicado: (2019)

Prevalence of dementia and mild cognitive impairment in indigenous Bolivian forager‐horticulturalists
por: Gatz, Margaret, et al.
Publicado: (2022)

Anti-amyloid-β Monoclonal Antibodies as Promising Disease-Modifying Therapies in Alzheimer’s Disease: A Focus on Aducanumab, Lecanemab, Crenezumab, Gantenerumab and Solanezumab
por: Melo, V. S. D., et al.
Publicado: (2023)

The Influence of Gender and Sexual Orientation on Alcohol Use and Alcohol-Related Problems: Toward a Global Perspective
por: Hughes, Tonda L., et al.
Publicado: (2016)

Marked gender differences in progression of mild cognitive impairment over 8 years
por: Lin, Katherine A., et al.
Publicado: (2015)

Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease
por: Maher-Edwards, Gareth, et al.
Publicado: (2015)

Economic impacts of introducing diagnostics for mild cognitive impairment Alzheimer's disease patients
por: Wittenberg, Raphael, et al.
Publicado: (2019)

A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment
por: Pink, Anna, et al.
Publicado: (2021)

Suicidal ideation and behavior assessment in dementia studies: An Internet survey
por: Chappell, Phillip, et al.
Publicado: (2016)

Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease
por: Gelmont, David, et al.
Publicado: (2016)

Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study
por: Landen, Jaren W., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f7qva0ko5o175j7fkg25fvrvt9